Compare OneSpan Inc (OSPN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Revvity Inc — how do they compare? OneSpan Inc trades at $18.22 (market cap $662.97M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 25.6× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Revvity Inc for 12 Days on average.
| OSPN | RVTY | |
|---|---|---|
Market Cap | $662.97M | $16.98B |
Volume | 616,882 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $18.42 | $157.36 |
52-Week Low | $10.15 | $82.26 |
Typical Hold Time | 18 Days | 12 Days |
Enterprise Value | $632.05M | $19.30B |
Dividend Yield | 2.89% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSPN trades at $18.22, up 2.94% today, with a bullish technical signal from moving averages and recent earnings beats. The company shows strong profitability with a 27.76% net income margin and a reasonable P/E of 10.16. Analyst consensus is strongly positive with 10 buy ratings. Recent news highlights investor attention and a new product launch, DigipassONE, supporting growth prospects.
The outlook for OSPN is favorable given consistent earnings outperformance and solid fundamentals, though negative net cash flow and competitive pressures pose risks. Upside potential hinges on execution of its subscription revenue growth strategy and market adoption of new authentication solutions.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
